Stocks · News reference
Jade Biosciences announced the presentation of three posters regarding its JADE101 program at ASN Kidney Week 2026 and confirmed the acceleration of its Phase 3 EVERGREEN clinical trial.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out
Jade Biosciences, Inc. will participate in four upcoming healthcare investor conferences in November 2026, featuring fireside chats and one-on-one meetings.
HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $55 price target.
Filed: 2026-09-30 AccNo: 0001193125-26-408287 Size: 162 KB Item 8.01: Other Events